Interestingly, LCN2 has also been previously proposed as a potential disease biomarker in the autoimmune disease systemic lupus erythematosus (SLE), as elevated levels of anti-LCN2 were detected in serum samples from patients with SLE [54]. This evidence concerns the gene LCN2 and systemic lupus erythematosus.